SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
NPCE reported Third Quarter 2026 results. The price and volatility reaction is pending.
NPCEearnings

Earnings reactions, page 3

NeuroPace, Inc. (NPCE) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue was $23.1 million in the third quarter of 2026.
  • RNS System revenue was $22.9 million in the third quarter of 2026.
  • Non-GAAP gross margin for the third quarter of 2026 was 84.8%.
  • Total GAAP gross margin from continuing operations in the third quarter of 2026 was 84.3%.
  • Non-GAAP operating expenses in the third quarter of 2026 were $19.2 million.
  • Adjusted EBITDA was $0.4 million for the third quarter of 2026.

Guidance

  • Full year 2026 total revenue guidance of $91 million to $92 million.
  • Full year 2026 non-GAAP gross margin guidance of 83.0% to 83.5%.
  • Full year 2026 non-GAAP operating expenses guidance of $85 million to $86 million.
  • Full year 2026 Adjusted EBITDA guidance of ($8.5) million to ($9.5) million.

Notes

The Company’s DIXI Medical product operations are presented as discontinued operations; prior-period amounts have been reclassified on a comparable basis.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →